Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use

Diabetes, Obesity and Metabolism

Volumn 19, Issue 1, 2017, Pages 13-23

  Taleb, Nadine ^a,b   Haidar, Ahmad ^c,d   Messier, Virginie ^a   Gingras, Véronique ^a,b   Legault, Laurent ^e   Rabasa Lhoret, Rémi ^a,b,f  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MONTREAL CHILDREN S HOSPITAL   (Canada)

^f Montreal Diabetes Research Center   (Canada)

Author keywords

external artificial pancreas; glucagon; glycaemic control; hypoglycaemia; type 1 diabetes

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 21; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCOSE; GLYCOGEN; INSULIN; POTASSIUM; SODIUM GLUCOSE COTRANSPORTER 2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HORMONE;

ADIPOSE TISSUE; ARTIFICIAL PANCREAS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; DEVICE SAFETY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ENERGY EXPENDITURE; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE METABOLISM; HEADACHE; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY BLOOD FLOW; LIPID METABOLISM; LIVER METABOLISM; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MOLECULAR DYNAMICS; NAUSEA; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; VOMITING; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; INSULIN INFUSION; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; GLUCAGON; HORMONES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PANCREAS, ARTIFICIAL;

EID: 85002903623     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12789     Document Type: Review

References (132)

1. Staub A, Sinn L, Behrens OK. Purification and crystallization of glucagon. J Biol Chem. 1955;214(2):619-632.
2. Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol. 2013;9:425-433.
3. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011;7:385-395.
4. Jr Taborsky GJ. The physiology of glucagon. J Diabetes Sci Technol. 2010;4:1338-1344.
5. Quesada I, Tudurí E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol. 2008;199:5-19.
6. Haidar A, Smaoui MR, Legault L, Rabasa-Lhoret R. The role of glucagon in the artificial pancreas. Lancet Diabetes Endocrinol. 2016;8587:1-3.
7. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med. 2015;373:2129-2140.
8. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013;185:297-305.
9. Renard E, Farret A, Kropff J, et al. Day and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previously reported feasibility study of evening and night at home. Diabetes Care. 2016;39:dc160008.
10. Kropff J, Del Favero S, Place J, et al. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016;3:939-947.
11. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325.
12. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-lhoret R. Comparison of dual-hormone artificial pancreas, single- hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 2014;8587:1-10.
13. Haidar A, Rabasa-lhoret R, Legault L, et al. Single- and dual-hormone artificial pancreas for overnight glucose control in type 1 diabetes. J Clin Endocrinol Metab. 2016;101:214-223.
14. Haidar A, Legault L, Matteau-pelletier L, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2015;8587:1-10.
15. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2:27ra27.
16. Russell S. When you come to a fork in the road, take it!. Lancet Diabetes Endocrinol. 2015;3:2-3.
17. Furuta M, Zhou A, Webb G, et al. Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. Diabetes. 2001;276:27197-27202.
18. Barnes TM, Otero YF, Elliott AD, et al. Metabolic Control by Inflammation and Immunity Interleukin-6 amplifies glucagon secretion: coordinated control via the brain and pancreas. Am J Physiol Endocrinol Metab. 2014;307(10):E896-E905.
19. Rohrer M, Berger MM, Pittet YK, Delodder F, Tappy L. Metabolic and physiologic effects of an endotoxin challenge in healthy obese subjects. Clin Physiol Funct Imaging. 2011;31:371-375.
20. Gromada J, Franklin I, Wollheim CB. A-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev. 2007;28:84-116.
21. Gylfe E. Glucose control of glucagon secretion: there is more to it than KATP Channels. Diabetes. 2013;62:1391-1393.
22. Macdonald PE, De Marinis YZ, Ramracheya R, et al. A K ATP channel-dependent pathway within a cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol. 2007;5:e143.
23. Zhang Quan, Ramracheya Reshma, Lahmann Carolina, et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013;18:871-882.
24. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-517.
25. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med. 1971;285:443-449.
26. Unger RH. Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes. 1971;20:834-838.
27. Behrman RGA, Kissebah AH, Wynn V. Diurnal patterns of plasma glucagon and insulin in normal and diabetic subjects. Horm Metab Res. 1978;10:459-465.
28. Segel SA, Paramore DS, Cryer PE. Hypoglycaemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724-733.
29. Siafarikas A, Johnston RJ, Bulsara MK, O'Leary P, Jones TW, Davis EA. Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes. Diabetes Care. 2012;35:1757-1762.
30. Cooperberg BA, Cryer PE. Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care. 2009;32:2275-2280.
31. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369(4):362-372.
32. Burcelin R, Knauf C, Cani PD. Pancreatic α -cell dysfunction in diabetes. Diabetes Metab. 2008;34(2):S49-S55.
33. Diabetes Research in Children Network (DirecNet) Study Group. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care. 2009;32:1954-1959.
34. Kramer CK, Retnakaran R, Zinman B. Response to comment on Kramer et al. Glucagon response to oral glucose challenge in type 1 diabetes: lack of impact of euglycemia. Diabetes Care 2014;37:1076–1082. Diabetes Care. 2014;37:e209.
35. Hare KJ, Vilsbøll T, Holst JJ, Knop FK. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. Am J Physiol Endocrinol Metab. 2010;298:E832-E837.
36. Brown RJ, Slnaii N, Rother KI. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care. 2008;31:1403-1404.
37. Fredheim S, Andersen M-LM, Pörksen S, et al. The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes. Diabetologia. 2014;58:828-834.
38. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283:109-115.
39. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes. 2010;59:2697-2707.
40. Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism. 2005;54:1168-1173.
41. Authier F, Desbuquois B. Glucagon receptors. Cell Mol Life Sci. 2008;65:1880-1899.
42. Jiang GZB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003;284:E671-E678.
43. Mithieux G, Gautier-stein A, Inserm U, Lyon D. Intestinal glucose metabolism revisited. Diabetes Res Clin Pract. 2014;105:295-301.
44. Lecavalier L, Bolli G, Cryer P, Gerich J. Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans. Am J Physiol. 1989;256:E844-E851.
45. Roach PJ. Control of glycogen synthase by hierarchal protein phosphorylation. FASEB J. 1990;4:2961-2968.
46. Hellman B, Salehi A, Gylfe E, Dansk H, Grapengiesser E. Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets. Endocrinology. 2009;150:5334-5340.
47. Gauthier M, Lavoie J. Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. Int J Sports Med. 2005;26:432-441.
48. El Youssef J, Castle JR, Bakhtiani PA, et al. Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care. 2014;37:3054-3060.
49. Hwang JH, Perseghin G, Rothman DL, et al. Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest. 1995;95:783-787.
50. Bischof MG, Krssak M, Krebs M, et al. Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes. 2001;50:392-398.
51. Cameron JM, Melrose AG. Changes in liver, pancreatic and stomach morphology following chronic glucagon administration in guinea-pigs. Br J Exp Pathol. 1962;43:384-386.
52. Root MA. Effect of glucagon on glycogen in rats and rabbits. Endocrinology. 1956;59:340-346.
53. Castle JR, El Youssef J, Bakhtiani PA, et al. Effect of repeated glucagon doses on hepatic glycogen in type 1 diabetes: implications for a bihormonal closed-loop system. Diabetes Care. 2015;38:4-8.
54. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care. 1994;17:734-755.
55. Åman J, Wranne L. Hypoglycaemia in childhood diabetes I. Acta Paediatr. 1988;77:542-547.
56. Blauw H, Wendl I, Devries JH, Heise T, Jax T. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels. Diabetes Obes Metab. 2016;18:34-39.
57. Hartley M, Thomsett MJ, Cotterill AM. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health. 2006;42:108-111, doi:10.1111/j.1440-1754.2006.00807.x.
58. Ranjan A, Schmidt S, Madsbad S, Holst JJ, Norgaard K. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes. Diabetes Obes Metab. 2016;18:410-418.
59. Russell S, El-Khatib F. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35:2148-2155.
60. Haidar A, Legault L, Matteau-Pelletier L, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2015;3:595-604.
61. Blauw H, van Bon AC, Koops R, et al. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab. 2016;18:671-677.
62. Russell SJ, Hillard MA, Balliro C, et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016;4:233-243.
63. Haidar A, Duval C, Legault L. Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. J Diabetes Sci Technol. 2013;7:1507-1512.
64. Pharmacology C. (rDNA ORIGIN) Eli Lilly Company:1–7. Available at: http://pi.lilly.com/us/rglucagon-pi.pdf
65. Schade DS, Woodside W, Eaton RP. The role of glucagon in the regulation of plasma lipids. Metabolism. 1979;28:874-886.
66. Longuet C, Sinclair EM, Maida A, et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 2008;8:359-371.
67. Højbjerg Gravholt C, Møller N, Jensen MD, Christiansen JS, Schmitz O. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab. 2001;86:2085-2089.
68. Jensen MD, Heiling VJ, Miles JM. Effects of glucagon on free fatty acid metabolism in humans. J Clin Endocrinol Metab. 1991;72:308-315.
69. Xiao C, Pavlic M, Szeto L, Patterson BW, Lewis GF. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes. 2011;60:383-390.
70. Guettet C, Rostaqui N, Mathe D, Lecuyer B, Navarro N, Jacotot B. Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats. Lipids. 1991;26:451-458.
71. Guettet C, Mathé D, Navarro N, Lecuyer B. Effects of chronic glucagon administration on rat lipoprotein composition. Biochim Biophys Acta. 1989;1005:233-238.
72. Guettet C, Mathe D, Riottot M, Lutton C. Effects of chronic glucagon administration on cholesterol and bile acid metabolism. Biochim Biophys Acta. 1988;963:215-223.
73. Merino B, Quesada I, Hernández-Cascales J. Glucagon increases beating rate but not contractility in rat right atrium. Comparison with isoproterenol. PLoS One. 2015, 10:e0132884 doi:10.1371/journal.pone.0132884.
74. Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med. 1968;279:12-17.
75. Nord HJ, Fontanes AL, Jr Williams JF. Treatment of congestive heart failure with glucagon. Ann Intern Med. 1970;72:649-653.
76. Arstila M, Iisalo E, Kallio V, Nousiainen R, Viljanen M. The effect of a long-acting glucagon preparation on endocrine and metabolic responses in acute myocardial infarction. Acta Med Scand. 1974;196:423-430.
77. Takayama S, Nakajima Y, Toma S, Sakamoto T. Increased muscle sympathetic nerve activity after glucagon administration in man. J Auton Nerv Syst. 1995;54:171-175.
78. Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41:595-602.
79. St-Onge M, Dubé PA, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol. 2014;52:926-944.
80. Shepherd G. Treatment of poisoning caused by β-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006;63:1828-1835.
81. Maroko PR, Kjekshus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971;43:67-82.
82. Goodwin GW, Taegtmeyer H. Metabolic recovery of isolated working rat heart after brief global ischemia. Am J Physiol. 1994;267:H462-H470.
83. Ussher JR, Baggio LL, Kabir MG, et al. Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab. 2014;4(2):132-143.
84. Eddy JD, O'Brien ET, Singh SP. Glucagon and haemodynamics of acute myocardial infarction. Br Med J. 1969;4:663-665.
85. ® trial. Eur Heart J. 2016;37(19):1526-1534. doi:10.1093/eurheartj/ehv728.
86. Pettit GW, Vick RL, Kastello MD. The contribution of renal and extrarenal mechanisms to hypokalemia induced by glucagon. Eur J Pharmacol. 1977;41:437-441.
87. Burton SD, Mondon CE, Ishida T. Dissociation of potassium and glucose efflux in isolated perfused rat liver. Am J Physiol. 1967;212:261-266.
88. Massara F, Martelli S, Cagliero E, Camanni F, Molinatti GM. Influence of glucagon on plasma levels of potassium in man. Diabetologia. 1980;417:414-417.
89. Cagliero E, Martina V, Molinatti GM. Diabetologia. 1983;1:85-87.
90. Parving HH, Noer J, Kehlet H, Mogensen CE, Svendsen PA, Heding L. The effect of short-term glucagon infusion on kidney function in normal man. Diabetologia. 1977;13:323-325.
91. Farah AE. Glucagon and the circulation. Pharmacol Rev. 1983;35:181-217.
92. Schwartz Sørensen S, Eiskjaer H, Orskov H, Bjerregaard Pedersen E. Effect of intravenous glucagon infusion on renal haemodynamics and renal tubular handling of sodium in healthy humans. Scand J Clin Lab Invest. 1993;53:25-34.
93. Hoogenberg K, Dullaart RP, Freling NJ, Meijer S, Sluiter WJ. Contributory roles of circulatory glucagon and growth hormone to increased renal haemodynamics in type 1 (insulin-dependent) diabetes mellitus. Scand J Clin Lab Invest. 1993;53:821-828.
94. Parving HH, Christiansen JS, Noer I, Tronier B, Mogensen CE. The effect of glucagon infusion on kidney function in short-term insulin-dependent juvenile diabetics. Diabetologia. 1980;19:350-354.
95. Wilson JE, Nelson RN. Glucagon as a therapeutic agent in the treatment of asthma. J Emerg Med. 1990;8:127-130.
96. Melanson SW, Bonfante G, Heller MB. Nebulized glucagon in the treatment of bronchospasm in asthmatic patients. Am J Emerg Med. 1998;16:272-275.
97. Wilber ST, Wilson JE, Blanda M, Gerson LW, Meerbaum SO, Janas G. The bronchodilator effect of intravenous glucagon in asthma exacerbation: a randomized, controlled trial. Ann Emerg Med. 2000;36:427-431.
98. Bisgard GE, Will JA. Glucagon and aminophylline as pulmonary vasodilators in the calf with hypoxic pulmonary hypertension. Chest. 1977;71:263-265.
99. Imbruce R, Goldfedder A, Maguire W, Briscoe W, Nair S. The effect of glucagon on airway resistance. J Clin Pharmacol. 1975;15:680-684.
100. Diamond G, Forrester J, Danzig R, Parmley WW, Swan HJ. Haemodynamic effects of glucagon during acute myocardial infarction with left ventricular failure in man. Br Heart J. 1971;33:290-295.
101. Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des. 2004;10:1325-1340.
102. Mighiu PI, Yue JTY, Filippi BM, et al. Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med. 2013;19:766-772.
103. Heppner KM, Habegger KM, Day J, et al. Glucagon regulation of energy metabolism. Physiol Behav. 2010;100:545-548.
104. Inokuchi A, Oomura Y, Nishimura H. Effect of intracerebroventricularly infused glucagon on feeding behavior. Physiol Behav. 1984;33:397-400.
105. Penick SB, Hinkle LE Jr. Depression of food intake induced in healthy subjects by glucagon. N Engl J Med. 1961;264:893-897.
106. Schulman JL, Carleton JL, Whitney G, Whitehorn JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol. 1957;11:419-421.
107. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab. 1987;64:896-901.
108. Leroux C, Brazeau A-S, Gingras V, Desjardins K, Strychar I, Rabasa-Lhoret R. Lifestyle and cardiometabolic risk in adults with type 1 diabetes: a review. Can J Diabetes. 2014;38:62-69.
109. Miller RE, Chernish SM, Brunelle RL. Gastrointestinal radiography with glucagon. Gastrointest Radiol. 1979;4:1-10.
110. Miller RE, Chernish SM, Brunelle RL, Rosenak BD. Dose response to intramuscular glucagon during hypotonic radiography. Radiology. 1978;127:49-53.
111. Hashimoto T, Adachi K, Ishimur NA, et al. Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy--a comparative study with butyl scopolamine bromide. Aliment Pharmacol Ther. 2002;16:111-118.
112. Ranganath L, Schaper F, Gama RML. Mechanism of glucagon-induced nausea. Clin Endocrinol (Oxf). 1999;51:260-261.
113. Stunkard AJ, VAN Itallie TB, REIS B. The mechanism of satiety: effect of glucagon on gastric hunger contractions in man. Proc Soc Exp Biol Med. 1955;89:258-261.
114. Simsek Y, Karaca Z, Tanriverdi F, Unluhizarci K, Selcuklu A, Kelestimur F. A comparison of low-dose ACTH, glucagon stimulation and insulin tolerance test in patients with pituitary disorders. Clin Endocrinol (Oxf). 2015;82:45-52.
115. Leong KS, Walker AB, Martin I, Wile D, Wilding J, MacFarlane IA. An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clin Endocrinol (Oxf). 2001;54:463-468.
116. Spathis GS, Bloom SR, Jeffcoate WJ, et al. Subcutaneous glucagon as a test of the ability of the pituitary to secrete GH and ACTH. Clin Endocrinol (Oxf). 1974;3:175-186.
117. Uebanso T, Taketani Y, Yamamoto H, et al. Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? PLoS One. 2011;6:4-11.
118. Cyphert HA, Alonge KM, Ippagunta SM, Hillgartner FB. Glucagon stimulates hepatic FGF21 secretion through a PKA- and EPAC-dependent posttranscriptional mechanism. PLoS One. 2014;9:e94996.
119. Arafat AM, Kaczmarek P, Skrzypski M, et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia. 2013;56:588-597.
120. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:696.
121. Ouedraogo R, Näslund E, Kirchgessner AL. Glucose regulates the release of orexin-A from the endocrine pancreas. Diabetes. 2003;52:111-117.
122. Göncz E, Strowski MZ, Grötzinger C, et al. Orexin-a inhibits glucagon secretion and gene expression through a Foxo1-dependent pathway. Endocrinology. 2008;149:1618-1626.
123. Arafat AM, Kaczmarek P, Skrzypski M, et al. Glucagon regulates orexin A secretion in humans and rodents. Diabetologia. 2014;57:2108-2116.
124. Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev. 2015;20:63-73.
125. Perfect MM, Patel PG, Scott RE, et al. Sleep, glucose, and daytime functioning in youth with type 1 diabetes. Sleep. 2012;35:81-88.
126. Pillar G, Schuscheim G, Weiss R, et al. Interactions between hypoglycemia and sleep architecture in children with type 1 diabetes mellitus. J Pediatr. 2003;142:163-168.
127. Pohl R, Li M, Krasner A, De Souza E. Development of stable liquid glucagon formulations for use in artificial pancreas. J Diabetes Sci Technol. 2015;9:8-16.
128. Onoue S, Ohshima K, Debari K, et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21:1274-1283.
129. Newswanger B, Ammons S, Phadnis N, et al. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Technol. 2015;9:24-33.
130. Bakhtiani PA, Caputo N, Castle JR, et al. A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. J Diabetes Sci Technol. 2015;9:17-23.
131. Caputo N, Jackson MA, Castle JR, et al. Biochemical stabilization of glucagon at alkaline pH. Diabetes Technol Ther. 2014;16:1-12.
132. Ali MA, Dayan CM. Review: the importance of residual endogenous beta-cell preservation in type 1 diabetes. Br J Diabetes Vasc Dis. 2009;9:248-253.